They struggle in execution even the most ardent bulls can't deny this. It is best left in capable BP hands. Everything takes much longer than a normal bio would do it. To think that it will take longer than 3 years since data lock for a submission and approval is absurd. Time for more capable hands of big pharma to run this drug to its potential in terms of regulatory approvals and indication expansion. You can't keep operating in asynchronous mode doing 1 thing at a time in this industry.
News 
Market Data 
Discover 
